TY - JOUR
T1 - A greater extent of insomnia symptoms and physician-recommended sleep medication use predict fall risk in community-dwelling older adults
AU - Chen, Tuo Yu
AU - Lee, Soomi
AU - Buxton, Orfeu M.
N1 - Funding Information:
Dr. Buxton received subcontracts to Penn State from Mobile Sleep Technologies (National Science Foundation #1622766, National Institutes of Health R43AG056250); Dr. Buxton has received two investigator-initiated grants from Sepracor Inc. (now Sunovion; ESRC-0004 and ESRC-0977, ClinicalTrials.gov Identifiers NCT00555750, NCT00900159), and two investigator-initiated grants from Cephalon Inc. (now Teva; ClinicalTrials.gov Identifier: NCT00895570). Dr. Buxton received Speaker’s Bureau, CME and non-CME lecture honoraria and an unrestricted educational grant from Takeda Pharmaceuticals, North America. Dr. Buxton served as a consultant and expert witness for Dinsmore LLC, and received consulting fees for serving on the Scientific Advisory Board of Matsutani America and from the Wake Forest University Medical Center (NC). Dr. Buxton received speaking fees and/or travel support for speaking from Chevron; American Academy of Craniofacial Pain; National Heart, Lung, and Blood Institute; National Institute of Diabetes and Digestive and Kidney Diseases; National Postdoctoral Association; Oklahoma State University; Oregon Health Sciences University; SUNY Downstate Medical Center; American Diabetes Association; and New York University.
Publisher Copyright:
© 2017 Oxford University Press. All rights reserved.
PY - 2017/11/1
Y1 - 2017/11/1
N2 - Study Objectives: Cross-sectional studies suggest that insomnia symptoms are associated with falls in later life. This longitudinal study examines the independent and interactive effects of the extent of insomnia symptoms (i.e., multiple co-existing insomnia symptoms) and sleep medications on fall risk over a 2-year follow-up among community-dwelling older adults. Methods: Using data from the Health and Retirement Study (2006-2014, N = 6882, Mage = 74.5 years ± 6.6 years), we calculated the extent of insomnia symptoms (range = 0-4) participants reported (i.e., trouble falling asleep, waking up during the night, waking up too early, and not feeling rested). At each wave, participants reported recent sleep medications use and falls since the last wave, and were evaluated for balance and walking speed. Results: A greater burden of insomnia symptoms and using physician-recommended sleep medications at baseline independently predicted falling after adjusting for known risk factors of falling. The effects of insomnia symptoms on fall risk differed by sleep medications use. The extent of insomnia symptoms exhibited a positive, dose-response relation with risk of falling among those not using sleep medications. Older adults using physician-recommended sleep medications exhibited a consistently higher fall risk irrespective of the extent of insomnia symptoms. Conclusions: The number of insomnia symptoms predicts 2-year fall risk in older adults. Taking physician-recommended sleep medications increases the risks for falling in older adults, irrespective of the presence of insomnia symptoms. Future efforts should be directed toward treating insomnia symptoms, and managing and selecting sleep medications effectively to decrease the risk of falling in older adults.
AB - Study Objectives: Cross-sectional studies suggest that insomnia symptoms are associated with falls in later life. This longitudinal study examines the independent and interactive effects of the extent of insomnia symptoms (i.e., multiple co-existing insomnia symptoms) and sleep medications on fall risk over a 2-year follow-up among community-dwelling older adults. Methods: Using data from the Health and Retirement Study (2006-2014, N = 6882, Mage = 74.5 years ± 6.6 years), we calculated the extent of insomnia symptoms (range = 0-4) participants reported (i.e., trouble falling asleep, waking up during the night, waking up too early, and not feeling rested). At each wave, participants reported recent sleep medications use and falls since the last wave, and were evaluated for balance and walking speed. Results: A greater burden of insomnia symptoms and using physician-recommended sleep medications at baseline independently predicted falling after adjusting for known risk factors of falling. The effects of insomnia symptoms on fall risk differed by sleep medications use. The extent of insomnia symptoms exhibited a positive, dose-response relation with risk of falling among those not using sleep medications. Older adults using physician-recommended sleep medications exhibited a consistently higher fall risk irrespective of the extent of insomnia symptoms. Conclusions: The number of insomnia symptoms predicts 2-year fall risk in older adults. Taking physician-recommended sleep medications increases the risks for falling in older adults, irrespective of the presence of insomnia symptoms. Future efforts should be directed toward treating insomnia symptoms, and managing and selecting sleep medications effectively to decrease the risk of falling in older adults.
UR - http://www.scopus.com/inward/record.url?scp=85044510096&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85044510096&partnerID=8YFLogxK
U2 - 10.1093/sleep/zsx142
DO - 10.1093/sleep/zsx142
M3 - Article
C2 - 29029240
AN - SCOPUS:85044510096
SN - 0161-8105
VL - 40
JO - Sleep
JF - Sleep
IS - 11
M1 - zsx142
ER -